Search research articles
Contact Us
Filters
Showing results (71-80 of 88) with videos related to
Page
of 9
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN
|
April 28, 2021
Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial
Kamyar Kalantar-Zadeh, Gregory G Schwartz, Stephen J Nicholls, et al.
Biomedicines
|
April 30, 2021
Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro
Dean Gilham, Audrey L Smith, Li Fu, et al.
European Journal of Human Genetics : EJHG
|
August 26, 2010
Preparation and validation of the first WHO international genetic reference panel for Fragile X syndrome
Malcolm Hawkins, Jennifer Boyle, Kathleen E Wright, et al.
American Journal of Preventive Cardiology
|
August 30, 2022
Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease
Peter P Toth, Gregory G Schwartz, Stephen J Nicholls, et al.
Atherosclerosis
|
December 1, 2022
Epigenetic BET reader inhibitor apabetalone (RVX-208) counters proinflammatory aortic gene expression in a diet induced obesity mouse model and in human endothelial cells
Sylwia Wasiak, Laura M Tsujikawa, Emily Daze, et al.
Atherosclerosis
|
October 1, 2019
Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease
Mathias Haarhaus, Kausik K Ray, Stephen J Nicholls, et al.
Clinical Epigenetics
|
November 11, 2020
BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes
Sylwia Wasiak, Kim E Dzobo, Brooke D Rakai, et al.
Translational Neuroscience
|
January 15, 2024
The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activation <i>in vitro</i> and in a mouse model of systemic inflammation
Sylwia Wasiak, Li Fu, Emily Daze, et al.
Nutrients
|
June 26, 2026
Prune Consumption and Bone Health in Older Men: A One-Year Randomized Controlled Trial
Lauren T Ormsbee, Neda S Akhavan, Joseph Munoz, et al.
Journal of Alzheimer'S Disease : JAD
|
August 30, 2021
Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial
Jeffrey Cummings, Gregory G Schwartz, Stephen J Nicholls, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 88) with videos related to
Sort By:
Page
of 9
Clinical Journal of the American Society of Nephrology : CJASN
|
April 28, 2021
Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial
Kamyar Kalantar-Zadeh, Gregory G Schwartz, Stephen J Nicholls, et al.
Biomedicines
|
April 30, 2021
Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro
Dean Gilham, Audrey L Smith, Li Fu, et al.
European Journal of Human Genetics : EJHG
|
August 26, 2010
Preparation and validation of the first WHO international genetic reference panel for Fragile X syndrome
Malcolm Hawkins, Jennifer Boyle, Kathleen E Wright, et al.
American Journal of Preventive Cardiology
|
August 30, 2022
Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease
Peter P Toth, Gregory G Schwartz, Stephen J Nicholls, et al.
Atherosclerosis
|
December 1, 2022
Epigenetic BET reader inhibitor apabetalone (RVX-208) counters proinflammatory aortic gene expression in a diet induced obesity mouse model and in human endothelial cells
Sylwia Wasiak, Laura M Tsujikawa, Emily Daze, et al.
Atherosclerosis
|
October 1, 2019
Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease
Mathias Haarhaus, Kausik K Ray, Stephen J Nicholls, et al.
Clinical Epigenetics
|
November 11, 2020
BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes
Sylwia Wasiak, Kim E Dzobo, Brooke D Rakai, et al.
Translational Neuroscience
|
January 15, 2024
The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activation <i>in vitro</i> and in a mouse model of systemic inflammation
Sylwia Wasiak, Li Fu, Emily Daze, et al.
Nutrients
|
June 26, 2026
Prune Consumption and Bone Health in Older Men: A One-Year Randomized Controlled Trial
Lauren T Ormsbee, Neda S Akhavan, Joseph Munoz, et al.
Journal of Alzheimer'S Disease : JAD
|
August 30, 2021
Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial
Jeffrey Cummings, Gregory G Schwartz, Stephen J Nicholls, et al.
Page
of 9